Document is current

Article History

Received: 3 May 2022

Accepted: 13 July 2022

First Online: 27 July 2022

Declarations

:

: The study protocol was approved by local ethics committee of the Charité University Medicine Berlin (State Office for Health and Social Affairs – LAGeSo, 21-634_10-Haupt – IV E 10) and the local ethic committees of the participating centers throughout Germany. The investigators must obtain freely given written informed consent from every patient prior any procedures related to the clinical trial including the documentation of results of clinical routine procedures for trial purposes as set forth in the GCP-ICH guidelines, the respective European Union’s and national legislation.

: Not applicable.

: Greta Sommerhäuser: none.Annika Kurreck: expenses for travel and accomodations: Amgen.Sebastian Stintzing: honoraria for talks and CME activities: Amgen, Astra-Zeneca, Bayer, BMS, ESAI, LEO Pharma, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, Takeda; research funding: Merck KGaA, Pierre-Fabre, Servier, Roche.Volker Heinemann: honoraria for talks and advisory board role: Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, Astra-Zeneca, BMS; MSD, Novartis, Boehringer Ingelheim, Pierre-Fabre, Celgene, SIRTEX, Terumo, Oncosil, Seagen; research funding: Merck, Amgen, Roche, Sanofi, Boehringer-Ingelheim, SIRTEX, Servier.Ludwig Fischer von Weikersthal: honoraria for talks: Lilly, Novartis, Pierre-Fabre.Tobias Dechow: none.Florian Kaiser: honoraria: Astellas, GSK, MSD, Novartis und Elsevier.Meinolf Karthaus: none.Ingo Schwaner: honoraria from AbbVie, Amgen, AstraZeneca, Beigene, BMS, Celgene, Incyte, Janssen, Lilly, Novartis, Roche, Servier.Martin Fuchs: honoraria for talks: BMS, MSD, Pierre-Fabre, Roche, Sanofi, Servier.Alexander König: none.Christoph Roderburg: research funding: Servier.Inna Hoyer: none.Michael Quante: honoraria from MSD, Celgene, Lilly, Servier, Merk.Alexander Kiani: honoria and travel: Amgen, Roche.Stefan Fruehauf: none.Lothar Müller: none.Anke Reinacher-Schick: honoraria for talks: Amgen, Roche, Merck Serono, Bristol-Myers Squibb, MSD, MCI Group, AstraZeneca; advisory board member: Amgen, Roche, Merck Serono, Bristol-Myers Squibb, MSD, AstraZeneca, Pierre Fabre; travel support: Roche; Studies (trial support institution/study grant institution): Roche, Ipsen; funding of scientific investigations (studies and research): Roche, Celgene, Ipsen, Amgen, Alexion Pharmaceuticals, Astra Zeneca, Lilly, Servier, AIO Studien gGmbH, Rafael Pharmaceutics, Erytech Pharma, BioNTech; consulting or advisory role: BMS, Lilly, Sanofi, Incyte, Ipsen, Bayer, Bristol-Myers Squibb, Pierre Fabre, Eisai, MSD, Roche, SERVIER, AstraZeneca, Merck Serono; research funding: Servier; travel, accommodations: Ipsen, Pierre Fabre.Thomas Ettrich: consulting or advisory role: BMS, Lilly, Sanofi, Incyte, Ipsen, Bayer, Bristol-Myers Squibb, Pierre Fabre, Eisai, MSD, Roche, Servier, AstraZeneca, Merck Serono; research funding: Servier; travel, accommodations: Ipsen, Pierre Fabre.Arndt Stahler: honoria: Roche, Taiho Pharmaceutical, Servier; expenses for travel and accomodations: Roche, Merck KGaA, Amgen, Pfizer, Lilly Oncology.Dominik Modest: honoraria: Amgen, Merck, Servier, Pierrefabre, BMS, MSD, Incyte, Lilly, Sanofi, G1, Transgene, Seagen, Onkowissen; research funding (inst): Servier, Amgen.